[1]Dangas GD, Claessen BE, Caixeta A, Sanidas
EA,Mintz GS, Mehran R. In-stent restenosis in the drugeluting stent era. J Am Coll Cardiol. 2010;56:1897–1907.
[2]Shlofmitz E, Iantorno M, Waksman R. Restenosis
of drug-eluting stents: a new classification system based ondisease mechanism to guide treatment and state-of-the-art
review. Circ Cardiovasc Interv. 2019;12:e007023.
[3]Alfonso F, Byrne RA, Rivero F, Kastrati A.Current
treatment of in-stent restenosis. J Am Coll Cardiol.
2014;63:2659–2673.
[4]Welt FG, Rogers C. Inflammation and restenosis in
the stent era. Arterioscler Thromb Vasc Biol. 2002;22:1769–
1776.
[5]Joner M, Finn AV, Farb A, et al. Pathology of drugeluting stents in humans: delayed healing and late thrombotic
risk. J Am Coll Cardiol.2006;48:193–202.
[6]Otsuka F, Vorpahl M, Nakano M, et al. Pathology
of second-generation everolimus-eluting stents versus firstgeneration sirolimus- and paclitaxel-eluting stents in humans.
Circulation.2014;129:211–223.
[7]Mintz GS. Features and parameters of drugeluting
stent deployment discoverable by intravascular ultrasound.
Am J Cardiol. 2007;100:26m–35m.
[8]Tsunoda T, Nakamura M, Wada M, et al.Chronic
stent recoil plays an important role in restenosis of the right
coronary ostium. Coron Artery Dis. 2004;15:39–44.
[9]Ota T, Ishii H, Sumi T, et al. Impact of coronary stent
designs on acute stent recoil. J Cardiol.2014;64:347–352.
[10]Raber L, Mintz GS, Koskinas KC, et al. Clinical use
of intracoronary imaging. Part 1: Guidance and optimization
of coronary interventions. An expert consensus document of
the European Association of Percutaneous Cardiovascular
Interventions. EuroIntervention. 2018;14:656–677.
[11]Hecht HS, Polena S, Jelnin V, et al. Stent gap by
64-detector computed tomographic angiography relationship
to in-stent restenosis, fracture,and overlap failure. J Am Coll
Cardiol. 2009;54:1949–1959.
[12]Lee SY, Im E, Hong SJ, et al. Severe acute stent
malapposition after drug-eluting stent implantation:effects
on long-term clinical outcomes. J Am Heart Assoc.
2019;8:e012800.
[13]Hassan AK, Bergheanu SC, Stijnen T, et al. Late
stent malapposition risk is higher after drugeluting stent
compared with bare-metal stent implantation and associates
with late stent thrombosis. Eur Heart J. 2010;31:1172–1180.
[14]Sawaya FJ, Lefevre T, Chevalier B, et al.
Contemporary approach to coronary bifurcation lesion
treatment. J Am Coll Cardiol Intv. 2016;9:1861–1878.
[15]Chen X, Li X, Zhang JJ, et al. 3-year outcomes of
the DKCRUSH-V trial comparing DK Crush with provisional
stenting for left main bifurcation lesions.J Am Coll Cardiol
Intv. 2019;12:1927–1937.
[16]Camaj A, Giustino G, Claessen BE, et al. Effect of
stent diameter in women undergoing percutaneous coronary
intervention with early- and newgeneration drug-eluting
stents: from the WIN-DES Collaboration. Int J Cardiol.
2019;287:59–61.
[17]Elezi S, Dibra A, Mehilli J, et al. Vessel size and
outcome after coronary drug-eluting stent placement:results
from a large cohort of patients treated with sirolimus- or
paclitaxel-eluting stents. J Am Coll Cardiol. 2006;48:1304–
1309.
[18]Kastrati A, Dibra A, Mehilli J, et al. Predictive
factors of restenosis after coronary implantation of sirolimusor paclitaxel-eluting stents. Circulation.2006;113:2293–2300.
[19]Farooq V, Gogas BD, Serruys PW. Restenosis:
delineating the numerous causes of drug-eluting stent
restenosis. Circ Cardiovasc Interv. 2011;4:195–205.
[20]Eshtehardi P, Cook S, Wandel S, et al. Impact of
arterial injury on neointimal hyperplasia after implantation
of drug-eluting stents in coronary arteries: an intravascular
ultrasound study. Euro-Intervention. 2010;6:467–474.
[21]Lüscher TF, Steffel J, Eberli FR, et al. Drugeluting
stent and coronary thrombosis: biological mechanisms and
clinical implications. Circulation.2007;115:1051–1058.
[22]Giustino G, Mastoris I, Baber U, et al. Correlates and
impact of coronary artery calcifications in women undergoing
percutaneous coronary intervention with drug-eluting stents:
from the Women in Innovation and Drug-Eluting Stents(WINDES) Collaboration. J Am Coll Cardiol Intv.2016;9:1890–
1901.
[23]Otsuka F, Byrne RA, Yahagi K, et al. Neoatherosclerosis:
overview of histopathologic findings and implications for
intravascular imaging assessment. Eur Heart J. 2015;36:2147–
2159.
[24]Canan T, Lee MS. Drug-eluting stent fracture:incidence,
contributing factors, and clinical implications. Catheter
Cardiovasc Interv. 2010;75:237–245.
[25]Kastrati A, Mehilli J, Dirschinger J, et al.Intracoronary Stenting and Angiographic Results:Strut
Thickness Effect on Restenosis Outcome (ISAR-STEREO)
trial. Circulation. 2001;103:2816–2821.
[26]Bangalore S, Toklu B, Patel N, Feit F,Stone GW.
Newer-generation ultrathin strut drugelutingstents versus
older second-generation thicker strut drug-eluting stents for
coronary artery disease. Circulation. 2018;138:2216–2226.
[27]Teeuwen K, van der Schaaf RJ,Adriaenssens T, et
al. Randomized multicentertrial investigating angiographic
outcomes of hybrid sirolimus-eluting stents with
biodegradable polymer compared with everolimus-eluting
stents with durable polymer in chronic total occlusions:the
PRISON IV trial. J Am Coll Cardiol Intv. 2017;10: 133–143.